Monte Rosa to present Phase 1 GFORCE-1 data for MRT-8102 in elevated cardiovascular risk subjects
GLUE•Monte Rosa Therapeutics scheduled an Oct. 1 webcast to present Phase 1 GFORCE-1 results for MRT-8102, including safety and activity findings across multiple dose levels after four weeks of treatment.
1. Webcast and study findings
Monte Rosa Therapeutics scheduled an Oct. 1 webcast to present Phase 1 GFORCE-1 results for MRT-8102 in subjects with elevated cardiovascular risk. The company plans to disclose safety and activity findings across multiple dose levels following four weeks of treatment, with the update expected to highlight evidence of broad modulation of disease-driving processes linked to atherosclerotic cardiovascular disease.
